HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Aurantoside C Targets and Induces Apoptosis in Triple Negative Breast Cancer Cells.

Abstract
Triple negative breast cancer (TNBC) is a subtype of breast cancers that currently lacks effective targeted therapy. In this study, we found that aurantoside C (C828), isolated from the marine sponge Manihinea lynbeazleyae collected from Western Australia, exhibited higher cytotoxic activities in TNBC cells compared with non-TNBC (luminal and normal-like) cells. The cytotoxic effect of C828 was associated to the accumulation of cell at S-phase, resulting in the decline of cyclin D1, cyclin E1, CDK4, and CDK6, and an increase in p21. We also found that C828 inhibited the phosphorylation of Akt/mTOR and NF-kB pathways and increased the phosphorylation of p38 MAPK and SAPK/JNK pathways, leading to apoptosis in TNBC cells. These effects of C828 were not observed in non-TNBC cells at the concentrations that were cytotoxic to TNBC cells. When compared to the cytotoxic effect with the chemotherapeutic drugs doxorubicin and cisplatin, C828 was found to be 20 times and 35 times more potent than doxorubicin and cisplatin, respectively. These results indicate that C828 could be a promising lead for developing new anticancer agents that target TNBC cells.
AuthorsSumi Shrestha, Anabel Sorolla, Jane Fromont, Pilar Blancafort, Gavin R Flematti
JournalMarine drugs (Mar Drugs) Vol. 16 Issue 10 (Oct 01 2018) ISSN: 1660-3397 [Electronic] Switzerland
PMID30275391 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Glycosides
  • Pyrrolidinones
  • aurantoside C
Topics
  • Animals
  • Antineoplastic Agents (pharmacology)
  • Apoptosis (drug effects)
  • Cell Line, Tumor
  • Female
  • Glycosides (pharmacology)
  • Humans
  • MCF-7 Cells
  • Phosphorylation (drug effects)
  • Porifera (chemistry)
  • Pyrrolidinones (pharmacology)
  • S Phase (drug effects)
  • Signal Transduction (drug effects)
  • Triple Negative Breast Neoplasms (drug therapy, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: